Stockscreener 앱 받기
40.51
2.32%
0.92
Harmony Biosciences Holdings Inc 주식(HRMY)의 최신 뉴스
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Harmony Biosciences Shows Niche Pharma Momentum Nasdaq Today - Kalkine Media
What analysts say about Harmony Biosciences Holdings Inc stockAutomated Trading Signals & Missed Nvidia? Don’t Miss This One - earlytimes.in
Harmony Advances Pitolisant GR After Bioequivalence Success - Sleep Review
Harmony Biosciences Prepares to Court Investors at Key December Healthcare Conferences - MSN
Harmony Biosciences (HRMY) Shares Promising Phase 3 Trial Results for EPX-100 - GuruFocus
Harmony Biosciences reports positive data for Dravet syndrome drug By Investing.com - Investing.com South Africa
Harmony Biosciences shows seizure reduction in dravet syndrome trial - StreetInsider
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome - Business Wire
Marshall Wace LLP Increases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony’s Next-Gen Narcolepsy Drug Advances With Surprising New Results - MyChesCo
Capital Fund Management S.A. Invests $1.14 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
How supply chain issues affect Harmony Biosciences Holdings Inc. stockDividend Hike & Smart Allocation Stock Reports - Newser
How analysts rate Harmony Biosciences Holdings Inc. stock today2025 Trading Recap & Fast Exit and Entry Strategy Plans - Newser
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data By Investing.com - Investing.com South Africa
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences to present Dravet syndrome trial data at AES meeting - Investing.com Canada
Harmony Biosciences Valuation Outlook After Recent Share Price Rebound - Yahoo Finance
How Pitolisant GR Progress and New Orexin Agonist Will Impact Harmony Biosciences (HRMY) Investors - Yahoo Finance
Harmony Biosciences (HRMY): Reassessing Valuation After Positive Pitolisant Study and New Orexin 2 Agonist Trial - Yahoo Finance
A Look at Harmony Biosciences (HRMY) Valuation Following Key Pipeline Advancements and Positive Trial Results - simplywall.st
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting - Business Wire
Harmony Biosciences to present Dravet syndrome trial data at AES meeting By Investing.com - Investing.com South Africa
Harmony Biosciences (Nasdaq: HRMY) to share new EPX-100 Dravet data at 2025 AES - Stock Titan
Prudential Financial Inc. Has $4.79 Million Stake in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc Stock Analysis and ForecastPrice Momentum Alerts & Fast Growing Capital Gains - earlytimes.in
Mizuho Maintains Harmony Biosciences Holdings (HRMY) Outperform Recommendation - Nasdaq
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress By Investing.com - Investing.com South Africa
Harmony Biosciences Launches Early Trial of Promising Orexin Agonist - MSN
Mizuho raises Harmony Biosciences stock price target to $46 on pipeline progress - Investing.com Australia
HRMY Upgraded by Mizuho: Price Target Raised to $46 | HRMY Stock News - GuruFocus
Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating - marketscreener.com
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $46 at Mizuho - StreetInsider
Harmony Biosciences appoints Adam Zaeske as Chief Commercial Officer - MSN
Citi Global Healthcare Conference - marketscreener.com
Boston Partners Takes $19.40 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by American Century Companies Inc. - MarketBeat
Geode Capital Management LLC Raises Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
(HRMY) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
H.C. Wainwright maintains $75 target on Harmony Biosciences stock - MSN
Can Harmony Biosciences Holdings Inc. stock deliver surprise earnings beatEarnings Overview Summary & Verified Swing Trading Watchlist - BỘ NỘI VỤ
SG Americas Securities LLC Sells 15,390 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Jefferies Financial Group Inc. Purchases 26,326 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results - Investing.com Canada
1.08%
0.91%
자본화:
|
볼륨(24시간):